SGO News via Twitter - March 21-22

I appreciate the use of the #sgomtg hashtag by those advocates, gynecologic oncologists and researchers attending the SGO Annual meeting. It has allowed those of us unable to attend to stay on top of the research that can impact the lives of women with a gynecologic cancer.

This blog will cover tweets from the meeting dates March 21-22, 2016 .

Frey: Ovarian cancer survivorship data-acceptance of toxicities change as goals of treatment change. #SGOmtg pic.twitter.com/4W1LGHjlSw

— Annie Ellis (@Stigetta) March 21, 2016

The presentation by Dr Frey will be covered in a separate blog post.

L. Meyer - enhanced recovery pathway in gyn onc surgery results in improved post op day 1 fatigue, nausea, and drowsiness! #gyncsm #SGOmtg

— Shannon Westin (@ShannonWestin) March 21, 2016

You may find more information on enhanced recovery pathways in this journal article. (Enhanced Recovery in Gyneocologic Surgery http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913481/ )

Excellent distillation Lari Wenzel! Patients live longer AND better w/patient-centered outcomes research #SGOmtg pic.twitter.com/8nxpY67VWA

— Annie Ellis (@Stigetta) March 21, 2016

A. Fader - small numbers but encouraging activity of pembrolizumab in recurrent #endometrial cancer https://t.co/csqF6hHRHi #gyncsm #SGOmtg

— Shannon Westin (@ShannonWestin) March 21, 2016

#SGOmtg Dr Matulonis on Cabozantinib vs Weekly Packitaxel in recurrent #Ovariancancer no improvement in OS

— BJ Rimel (@BJRimelMD) March 21, 2016

PFS similar between all arms of GOG252 - dose dense vs IP with Cisplatin vs IP with Carboplatin. Now - to evaluate QOL! #gyncsm #SGOMtg

— Shannon Westin (@ShannonWestin) March 21, 2016

GOG 252 results at #sgomtg put into question the benefit of IP chemotherapy in newly dxed #ovariancancer pts

— Ursula Matulonis, MD (@DrMatulonis) March 21, 2016

@womenofteal The presentation after results was on QOL and PROs, which totally did not favor IP cis. And without a PFS benefit, it's tough.

— Erin Stevens (@erinstevensmd) March 22, 2016

Ovarian cancer surgery with a general surgeon increases the risk of ostomy without clear clinical benefit #SGOmtg pic.twitter.com/0PCtq3podc

— Leslie Clark (@lesliehclark) March 22, 2016

Scalici: CSC markers--compelling results. #SGOmtg pic.twitter.com/2hdIk6B3rk

— Annie Ellis (@Stigetta) March 22, 2016

CSC= cancer stem cell

BRCA mutations are linked to a longer survival in patients with ovarian cancer, study shows https://t.co/Ws5vv4jgCm #SGOmtg

— OncLive.com (@OncLive) March 21, 2016

Thank you to all the researchers who consider the needs of their patients as they develop better treatments, detection tests and a cure.

Dee
Every Day is a Blessing!